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Abstract: Little is known about genetic changes in squamous differentiation of non-schistosomiasis-associated blad-
der cancer. Therefore, we investigated pure squamous cell carcinomas (SqCC), squamous parts of mixed urothelial 
carcinomas with squamous differentiation (MIX) and mere urothelial cancers (UC) for structural genetic differences. 
Tissue microarray slides (n = 29 SqCC, n = 35 MIX and n = 23 UC) were analyzed by ZytoLight SPEC p16/CEN3/7/17 
Quadruple Color Probe fluorescence-in-situ-hybridization (FISH) and DNA was investigated by comparative genomic 
hybridization (CGH) (n = 35 SqCCs, n = 40 MIX and n = 36 UC). By FISH the mean number of polysomic cells was 
lowest in SqCC (CEN3 P = 0.0498, CEN17 P = 0.0009). A slight tendency of lower copy numbers of chromosomes 
3, 7 and 17 and higher numbers of the p16-locus in SqCC (P = 0.45) indicated less aneuploid tumor cells in SqCC 
compared to MIX and UC. In CGH SqCC showed the lowest mean number of aberrations per tumor (SqCC 5.37 
changes, MIX 6.75 and UC 7.64; P = 0.1754). Significant differences between the three groups were found for loss 
of chromosome 3p (P = 0.004), 6q (P = 0.028), 11p (P = 0.024) and gains of 5p (P = 0.020). Loss of 3p was more 
frequent in SqCC (51.4%) than in MIX (37.5%) or UC (13.9%). To conclude, SqCCs show less polysomy and genetic 
alterations than MIX and UC. Loss of 3p is more frequent in SqCC but there are no absolute specific alterations for 
each tumor group. Squamous parts of mixed tumors show similar alterations than UC and should be considered as 
further development of UC, while pure SqCC seem to be a separate tumor group. 
Keywords: Bladder cancer, urothelial carcinoma, urothelial carcinoma with squamous differentiation, squamous 
cell carcinoma, FISH, CGH 
Introduction
Pure squamous cell carcinoma (SqCC) of the 
urinary bladder comprises less than 5% of all 
bladder cancers [1-3]. However, it is more fre-
quent in certain subgroups like patients with 
chronic inflammation, urinary tract calculi or 
chronic bladder outlet obstruction, and in 
patients with spinal cord injury [1, 2, 4]. 
Additionally, higher numbers of SqCC were 
reported in regions with endemic schistosomia-
sis [5, 6]. According to the 2004 World Health 
Organization classification of bladder cancer 
the diagnosis of squamous cell carcinoma is 
reserved for tumors with complete squamous 
differentiation without any other tumor compo-
nent including urothelial carcinoma in situ [3]. 
Indeed, histologically identifiable focal squa-
mous differentiation in high grade urothelial 
carcinoma is a quite frequent finding reported 
in literature in up to 50% of tumors [7]. 
Additionally, recent advances in whole genome 
expression profiling revealed a subtyping of 
muscle invasive bladder cancer (MIBC) into 
breast cancer-like basal and luminal types, with 
identification of a “basal/squamous-like” sub-
type [8-10]. These cancers express higher lev-
els of high molecular weight keratins (KRT5, 
KRT6, KRT14) and EGFR [8, 9], show an inva-
sive/metastatic phenotype with shorter surviv-
Structural genetics of squamous bladder cancer
8144 Int J Clin Exp Pathol 2015;8(7):8143-8158
Table 1. Characteristics of the multicentric tumor cohort (classified according to the results of Gaisa 
et al., 2011 [15])
ID classification center year of  sampling sex age 
tumor 
grade pT pN L V R
1 MIX Aachen 2004 M 77 3 2 0 0 0 0
2 UC Aachen 2005 M 72 3 2 0 0 0 0
3 SqCC Aachen 2003 F 47 2 3 0 N/A N/A 0
5 SqCC Aachen 2005 M 78 3 3 N/A N/A N/A N/A
7 MIX Aachen 2006 F 66 3 3 0 N/A 1 0
10 SqCC Aachen 2005 F 81 3 4 0 N/A 1 1
11 SqCC Aachen 2006 F 63 3 3 N/A N/A N/A 0
12 MIX Aachen 2006 M 53 3 4b 2 1 N/A 0
22 UC Aachen 2004 M 64 2 3 0 1 0 0
24 UC Aachen 2006 M 77 3 3b 2 1 1 0
29 SqCC Aachen 2004 F 82 3 2 N/A N/A N/A N/A
30 UC Aachen 2005 M 58 3 2 0 0 0 0
32 UC Aachen 2006 F 84 3 2b 0 1 1 0
33 UC Aachen 2005 M 60 3 3 0 0 0 0
34 UC Aachen 2008 F 56 3 4a 1 0 0 x
35 UC Aachen 2008 M 82 3 2 N/A N/A N/A N/A
36 MIX Aachen 2004 F 35 3 3 N/A 0 0 1
39 SqCC Aachen 2006 F 57 2 3 0 0 0 0
41 SqCC München 2008 F 63 3 3a 0 1 1 0
43 UC Aachen 2003 M 77 2 3 0 1 0 0
44 UC Aachen 2006 M 76 3 3a 2 1 1 1
45 UC Aachen 2009 M 78 3 4a 1 1 1 1
46 UC Aachen 2006 M 94 3 3a N/A 0 1 0
47 UC Aachen 2004 M 48 3 3 0 0 0 0
56 MIX München 2008 F 47 2 2 0 0 0 0
62 MIX Aachen 2005 M 58 3 3 0 0 0 0
66 UC Aachen 2007 F 76 3 3 N/A 0 1 0
70 UC Aachen 2009 M 72 3 2b 0 0 0 0
71 UC Aachen 2005 M 74 3 2b 0 0 0 0
77 MIX Aachen 2005 M 60 3 3 0 0 0 0
38 UC Aachen 2005 M 60 3 3 0 0 0 0
78 UC Aachen 2006 M 70 3 4 3 1 0 1
80 MIX Aachen 2003 M 77 2 3 0 1 0 0
88 MIX Aachen 2007 F 76 3 3 N/A 0 1 0
89 MIX München 2007 F 71 3 3 N/A 0 0 0
90 MIX Aachen 2008 F 70 3 3 0 0 0 0
91 SqCC Aachen 2003 F 77 3 3 N/A N/A N/A N/A
98 SqCC Regensburg 2007 F 79 3 2 N/A N/A N/A N/A
102 SqCC Regensburg 2007 F 53 3 2 N/A N/A N/A N/A
107 SqCC Regensburg 1999 F 76 2 2 N/A N/A N/A 0
110 MIX Regensburg 2007 F 76 3 2 N/A N/A N/A N/A
113 MIX Regensburg 1994 F 71 2 2 N/A N/A N/A N/A
117 SqCC Regensburg 2005 M 49 3 3b 0 0 0 0
120 MIX Regensburg 2004 M 75 3 2 N/A N/A N/A N/A
121 SqCC Regensburg 2007 M 53 3 3 0 0 0 0
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125 MIX Regensburg 2002 F 76 3 3 0 N/A N/A 0
129 MIX Regensburg 2007 F 80 3 3a 1 1 1 0
132 SqCC Regensburg 2001 M 80 3 4 N/A N/A N/A N/A
135 SqCC Regensburg 2001 F 57 3 3 0 N/A N/A 1
136 SqCC Dresden 2003 M 82 3 3a 0 N/A N/A 0
138 MIX Dresden 2006 F 81 3 3b 0 0 0 1
141 MIX Dresden 2006 F 87 3 2a 0 N/A N/A 0
143 UC Dresden 2005 M 71 3 3b 0 1 1 0
146 MIX Dresden 2004 F 68 3 3a 0 N/A 1 0
148 MIX Dresden 2004 F 68 3 3b 2 1 0 0
150 MIX Dresden 2005 M 68 2 3a 0 1 0 N/A
152 MIX Dresden 2005 M 82 3 3b N/A 1 1 0
154 MIX Dresden 2006 F 84 3 3b 1 1 0 0
156 MIX Dresden 2006 M 52 3 3a 0 0 0 0
158 MIX Dresden 2001 F 80 2 3a 0 N/A N/A 0
160 MIX Dresden 2002 M 78 3 3b 0 N/A N/A 0
162 MIX Dresden 2002 M 61 3 3a 0 N/A N/A 0
163 MIX Dresden 2004 F 80 3 3b 2 1 0 0
167 SqCC Münster 2002 F 65 2 4 0 N/A N/A 0
170 SqCC Münster 2003 M 58 2 3 2 N/A N/A 1
173 MIX Münster 2003 F 62 3 3 N/A N/A N/A N/A
179 UC Münster 2003 M 68 2 2 0 N/A N/A N/A
180 MIX Münster 2003 M 68 2 2 0 N/A N/A N/A
182 SqCC Münster 2003 M 75 2 4 0 N/A 1 0
186 MIX Münster 2003 F 34 3 3b 0 N/A N/A 0
189 SqCC Münster 2003 F 43 2 3a 0 N/A N/A 0
195 MIX Münster 2003 M 65 3 3a 1 N/A N/A 0
197 SqCC Münster 1993 M 68 2 3b 0 N/A N/A N/A
199 SqCC Münster 1995 M 60 3 3b N/A N/A N/A 0
201 MIX Münster 1996 M 60 3 3b 0 1 N/A 0
206 SqCC Münster 1998 M 50 3 4b N/A N/A N/A 1
208 SqCC Münster 1999 M 69 3 3b 0 N/A N/A N/A
210 SqCC Münster 1999 M 34 3 3b 1 N/A N/A 0
212 MIX Münster 1999 F 68 3 3b N/A N/A N/A 0
214 MIX Münster 1999 M 59 3 3a 0 N/A N/A 0
217 MIX Münster 1999 F 74 3 4a 0 N/A N/A N/A
220 SqCC Münster 2000 F 61 2 3b N/A N/A N/A 0
222 MIX Münster 2002 M 74 3 3b N/A N/A N/A 0
224 SqCC Münster 2002 F 62 3 3a 0 N/A N/A 0
226 SqCC Münster 2002 M 75 2 3a 2 1 1 0
229 SqCC Münster 2002 M 63 2 2b 0 N/A N/A 0
231 SqCC München 2005 M 70 3 3b 0 N/A N/A N/A
233 MIX München 2005 F 88 3 3a 0 N/A N/A N/A
236 SqCC München 2006 F 64 2 3a N/A 1 N/A N/A
238 SqCC München 2006 M 62 3 2b 0 N/A N/A 0
240 SqCC München 2007 M 55 2 3a 0 N/A N/A 0
242 SqCC München 2007 F 58 2 2b 0 0 0 0
247 MIX Aachen 2008 F 79 3 4 0 0 1 0
252 MIX Aachen 2009 F 76 3 3 N/A 1 1 1
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al but are indifferent from conventional high 
grade urothelial carcinoma on hematoxylin 
eosin-based routine histological evaluation. In 
this context, there is a need to better under-
stand mere squamous differentiation and par-
tial squamous differentiation especially in non-
schistosoma-associated bladder cancers, to 
draw further conclusions and consequences of 
a “basal/squamous-like” subtype. However, 
previous studies on genetic aberrations in 
SqCC either focused on schistosomiasis-asso-
ciated tumors [11, 12], hardly separated schis-
tosomiasis-associated and non-schistosomia-
sis-associated SqCC or compared SqCC and 
squamous parts of mixed urothelial/squamous 
cancers in single cases only [13]. The most 
comprehensive study of structural genetic data 
on schistosoma- and non-schistosoma-associ-
ated SqCC and UC by El-Rifai et al. suggested 
different genetic pathways for these tumors 
due to varying gains and losses of chromo-
somes [14], but a detailed analysis of non-
schistosoma-associated SqCC and the squa-
mous part of mixed urothelial/squamous can-
cers (MIX) is also lacking. In a previous study 
our workgroup has evaluated squamous differ-
entiation in bladder cancers [15], and precisely 
immunophenotyped a cohort of patients with 
non-schistosomiasis-associated pure SqCC of 
the urinary bladder and mixed urothelial and 
squamous cancers. Given the paraffin material 
and histopathological data of this cohort, the 
aim of the study presented here was to evalu-
ate the structural genetic changes of the three 
bladder cancer subtypes non-schistosomiasis-
associated squamous carcinoma of the blad-
der (SqCC), mixed urothelial carcinoma with 
partial squamous differentiation (MIX) and pure 
urothelial carcinoma (UC) by fluorescence in 
situ hybridization and comparative genomic 
hybridization. 
Materials and methods
Specimens and preparations
Retrospectively diagnostic formalin-fixed paraf-
fin tissues (FFPE) from six Institutes of 
Pathology in Germany were collected. Cases 
were recruited between 1993 and 2009. In 
total we collected n = 35 pure squamous cell 
carcinoma (SqCC) and n = 40 mixed UC/SqCC 
(MIX). In a prior study of our workgroup tissue 
microarrays (TMAs) of these samples have 
been constructed and immunohistochemically 
evaluated [15]. For analysis of MIX tumors we 
used the squamous cell tumor part (completely 
positive for KRT5/6 and KRT5/14, but negative 
for KRT20) [15]. Additionally, n = 36 urothelial 
carcinomas (UC) from Aachen and Jena served 
as a control group. The age of the tissue blocks 
as well as the formalin concentrations, fixation 
times and paraffin composition among the 
samples were highly variable. An overview of 
cases is shown in Table 1.
Approval of the local ethics committee for retro-
spective use of diagnostic FFPE tissue was 
256 MIX Aachen 2005 M 72 3 3 0 1 1 0
259 SqCC Aachen 2008 F 54 3 4 0 N/A 0 N/A
J60 UC Jena 1996 M 68 3 2 N/A N/A N/A N/A
J66 UC Jena 1997 M 56 3 3 N/A N/A N/A N/A
J101 UC Jena 2001 M 67 3 3 2 N/A N/A N/A
J108 UC Jena 1997 M 58 3 3 N/A N/A N/A N/A
J135 UC Jena 1996 W 82 3 2 N/A N/A N/A N/A
J139 UC Jena 1996 M 57 2 3 N/A N/A N/A N/A
J143 UC Jena 1996 M 69 3 3 N/A N/A N/A N/A
J178 UC Jena 1997 M 72 3 2 N/A N/A N/A N/A
J223 UC Jena 1996 W 69 3 2 N/A N/A N/A N/A
J224 UC Jena 1996 M 71 3 2 N/A N/A N/A N/A
J228 UC Jena 1996 M 66 3 2 N/A N/A N/A N/A
J311 UC Jena 1999 M 58 3 2 N/A N/A N/A N/A
J381 UC Jena 1997 M 66 3 3 N/A N/A N/A N/A
J578 UC Jena 1997 M 66 3 2 2 N/A N/A N/A
ID = identification, SqCC = pure squamous cell carcinoma of the bladder, MIX = urothelial carcinoma with squamous differen-
tiation, UC = urothelial carcinoma, F = female, M = male, N/A = not available. 
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obtained (RWTH Aachen EK 9/12). Paraffin 
slides of TMAs were used for FISH, and DNA 
was extracted from paraffin slides of the resid-
ual tissue blocks after careful manual microdis-
section of tumor areas under a stereomicro-
scope using standard QiAampTM DNA Mini Kit 
(Qiagen, Hilden, Germany) according to the 
manufacturer’s orders.
Figure 1. Evaluation of tumor cell polysomy. A. Numbers 
of polysomic tumor cells of SqCC, MIX and UC regarding 
chromosome 3 (CEN 3 red). Cut off level is indicated by a 
horizontal broken line, mean is represented by a horizontal 
continuous line. NC = normal control. B. Categorization of 
tumors in negative (= diploid/normal) and positive (= poly-
somic) cases regarding polysomy of CEN3. C. Numbers of 
polysomic tumor cells of SqCC, MIX and UC regarding chro-
mosome 7 (CEN 7 green). D. Categorization of tumors in 
negative (= diploid/normal) and positive (= polysomic) cas-
es regarding polysomy of CEN7. E. Numbers of polysomic 
tumor cells of SqCC, MIX and UC regarding chromosome 
17 (CEN 17 blue). F. Categorization of tumors in negative (= 
diploid/normal) and positive (= polysomic) cases regarding 
polysomy of CEN17.
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Fluorescence in situ hybridization (FISH)
FISH was performed on 5 µm paraffin-slides of 
TMAs carrying both tumor and reference 
cores. ZytoLight SPEC p16/CEN3/7/17 Qua- 
druple Color Probes (Zytovision, Bremerhaven, 
Germany) was used according to the manufac-
turer’s protocol and standard in-house modifi-
cations for pretreatment of tissue sections. 
Signals were detected with an Axiovert S100 
Fluorescence Microscope (Carl Zeiss, Ober- 
kochen, Germany), suitable filter sets and 
DISKUS software (Hilgers, Technisches Buero, 
Koenigswinter, Germany). 
For each TMA hybridization efficacy was evalu-
ated on normal urothelium reference cores and 
for each patient signals of 50 tumor cell nuclei 
were counted. Polysomy of tumour cells was 
determined by a cut-off value in normal tissue 
cells according to the literature: mean number 
of polysomic cells + (standard deviation x 3). All 
cells with ≥3 signals were assumed to be poly-
somic [16].
Comparative genomic hybridization (CGH)
Due to highly variable DNA quality and subse-
quent problems in probe preparation for Array-
Figure 2. Differences of means of chromosome/locus copies of UC, MIX and SqCC. A. Box plot of CEN3 signals of 
SqCC, MIX and UC. Mean is indicated by a horizontal line. B. Box plot of CEN7 signals of SqCC, MIX and UC. C. Box 
plot of CEN17 signals of SqCC, MIX and UC. D. Box plot of SPEC p16 signals of SqCC, MIX and UC. 
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Table 2. All structural chromosomal aberrations detected with CGH
ID total changes losses gains ampli-fications
SqCC (n = 35)
    3 2 2 0 0 dim (3p, 10q)?
    39 4 2 2 0 dim (3p14pter, 18q13qter) enh (1q, 12p)
    107 0 0 0 0 no changes
    167 4 2 2 0 dim (6q, 12q21q24.1) enh (10p, 12p)
    170 3 2 1 0 dim (8p, 18q) enh (5p)
    182 8 3 5 0 dim (6q16.1q22.33, 17p, 20p) enh (3q21.1qter, 5q11.2q21.3, 9p, 10p12.33pter, 17q)
    189 3 1 2 0 dim (3p) enh (3q22.1qter, 9q12q21.31)
    197 3 3 0 0 dim (3p?, 8p?, 10q22.2qter)
    220 20 16 4 0 dim (2q21.2q23.2, 2q36.1qter, 3p, 4p, 4q31.3qter, 5q34qter, 6q22.31q26, 8p?, 9, 10q26.11qter, 11q23.2qter, 13q22.3qter, 15q, 18q, 20, 21q) 
enh (3q, 8q, 11q12.1q14.2, 18p)
    226 9 9 0 0 dim (2p15pter, 3p, 4p, 8p?, 9, 10q22.1qter, 11p, 13q21.1qter, 21)
    229 0 0 0 0 no changes
    236 0 0 0 0 no changes
    240 1 1 0 0 dim (20q)
    242 0 0 0 0 no changes
    5 6 5 1 0 dim (3p14pter, 4p, 9q, 10q22qter, 11q14qter) enh (9p)
    10 5 1 4 0 dim (10q) enh (1q, 3p21qter, 8, 17q23qter)
    11 9 4 4 1 dim (3p14pter, 5q32qter, 7q33qter, 8p) enh (3p14qter?, 7p, 8q11.2q23, 18) amp (11q14q23)
    29 5 3 2 0 dim (3p, 11q14.1qter, 18q?) enh (3q, 18p?)
    41 0 0 0 0 no changes
    91 6 4 2 0 dim (3p, 6q16qter, 10q22qter, 18q) enh (3q, 18p)
    98 0 0 0 0 no changes
    102 9 6 3 0 dim (2q35qter, 3p, 4q28.3qter, 5q11.2q31.1, 8p, 18q) enh (3q25.1qter, 11q12.2q13.4, 13q22.2pter)
    117 3 3 1 0 dim (8p, 14q31.1qter, 16?) enh (1p21.1p33)
    121 11 5 6 0 dim (2q22.1qter, 3p, 5q, 8qter?, 10q23.1qter) enh (1q21.1q25.3, 2p11.1p16.1, 7, 11, 18p, 20)
    132 1 1 0 0 dim (3p)
    135 4 4 0 0 dim (11q13, 15q22qter, 17, 20qter)
    136 4 2 2 0 dim (3p14p21, 16) enh (4q, 9p)
    199 4 1 3 0 dim (18q) enh (11q12q13.4, 16?, 17)
    206 12 7 5 0 dim (1p, 3p, 4p, 4q26qter, 8p, 14, 21q) enh (2q31.2q35, 5p, 7q, 9q, 12p)
    208 13 5 8 0 dim (3p, 5q, 6q15q22.33, 10q26.11qter,18) enh (6p, 8q22.1qter, 9q, 12p12.3q21.3, 13q14.11qter, 17q, 20, 21)
    210 12 3 9 0 dim (3p, 11q21qter, 15q) enh (1p34.1p35.1, 5p, 6p, 7p13q21.11, 8q22.3q23.3, 9, 11q13.2q14.3, 17p, 20)
    224 8 6 2 0 dim (2q, 6q, 9q, 11q14.1qter, 13q, 20p) enh (18p, 20q)
    231 1 0 1 0 enh (1q31.1q32.2)
    238 7 4 3 0 dim (3p11.2p21.33, 8p, 10q25.1qter, 18q) enh (6p21.33pter, 8q?,18p?)
    259 11 5 6 0 dim (5q, 7q31.13qter?, 11q21qter, 13q, 18q) enh (3q25.1qter, 5p, 7q31.1pter, 8q21.1qter, 11q12.2p13.3, 14)
MIX (n = 40)
    80 3 1 2 0 dim (10q23qter) enh (5p, 6q12q23)
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    150 4 4 0 0 dim (9, 10q24.2qter, 11, 17p)
    158 4 4 0 0 dim (6p?, 15q22qter, 17p, 20)
    180 21 13 8 0 dim (1p, 2p, 2q34qter, 3p, 4p, 4q26qter, 5q, 10q23.31q25.3, 11p, 11q23.1qter, 17p, 18q, 20p) enh (5p, 6p, 6q21q24, 7p, 8p, 10p, 
11q12.1q14.1, 20q)
    56 5 3 2 0 dim (3p12p14, 7q, 10q21qter?) enh (3q, 7p)
    113 0 0 0 0 no changes
    1 8 5 3 0 dim (2p?, 2q33qter, 8p, 11q23qter, 16q21qter) enh (1p12p31, 8q11.22q23.1, 12q14q21)
    6 0 0 0 0 no changes
    12 13 6 7 0 dim (3p, 8p, 9p13pter, 10q22.2q23, 11p, 11q23qter) enh (1q21qXq31.3, 5p13.2p14.3, 6q22.3qter, 7q?, 8q21.1qter, 9q?, 10p11.2p13)
    62 0 0 0 0 no changes
    88 5 1 4 0 dim (11q14qter) enh (1q, 3q26qter, 7p12.2q32, 8q23.1qter)
    90 8 6 2 0 dim (3p?, 6p21p22?, 9q22.3qter, 10q22qter, 15q22qter, 18q?) enh (5p, 8q)
    110 16 5 11 0 dim (3p14.1p24, 6p, 11p, 16q, 17q24.2pter) enh (1q, 2p11.2p21, 3q, 4q13.2q24, 5q11.2q14.2, 6q, 8q23.1qter, 10p, 12p, 16p, 20q)
    120 7 1 6 0 dim (3p12.2p23) enh (1q12q32.2, 3q, 5p?, 7, 8q, 9)  
    125 6 6 0 0 dim (3p14.3p21.3, 10q21.1qter, 11q12.3q13.4?, 16, 17p?, 20q)
    148 9 6 3 0 dim (3p14.1pter, 10q22.1qter, 15q22.1qter, 16, 17p, 20) enh (3p14.1qter, 5p, 9q21.3qter)
    152 10 9 1 0 dim (2q36.1qter, 3p12.1p21.32, 4q, 5q, 7q32.3qter, 11q22.3qter, 15q22.1qter, 16p, 20q13.12qter) enh (5p)
    154 4 2 2 0 dim (8p, 16?) enh (1? oder 1p33q31.3, 12q21.1q23.2)
    156 0 0 0 0 no changes
    160 7 3 3 1 dim (9q22.3qter, 16p, 17q25.1pter) enh (1p32q32, 3q, 5p) amp (12p)
    162 10 7 3 0 dim (1q31.3qter, 2q34qter, 3p14.1p22.1, 9q31.1qter, 1q24.2qter, 15q22.1qter, 16q) enh (11q14.1q24.1, 13q21.1qter, 18p)
    173 11 8 3 0 dim (1?, 2?, 4q28qter, 10q, 11p, 11q21qter, 15q, 18q) enh (5p, 8q21.1qter, 18p)
    195 8 4 4 0 dim (3p, 3q12.3q21.2, 4, 5q) enh (2q23.2q33.2, 6p21.31pter, 1p14.1q12.1, 12p)
    214 5 1 4 0 dim (18q) enh (5p, 7q12.1q21.12, 17p, 20)
    233 8 3 5 0 dim (5q32qter, 6p, 9q21.13qter, 18q) enh (3q26.2qter, 8q, 10p, 12p, 20?)
    252 6 0 6 0 enh (1q, 7?, 12, 16?, 17?, 20)
    256 5 3 2 0 dim (6q22.1qter, 10q25.1qter, 13q31.1) enh (3q24qter?, 10p)
    186 8 8 0 0 dim (2q34qter, 3p11.1p21.3, 4q21.22qter, 5q, 7q22.2qter, 11q21qter, 13q12.11q21.1, 18q21.31qter)
    201 10 7 3 0 dim (4p, 5q32qter, 8p, 9, 10q25.1qter, 11p, 21q) enh (5p, 8q, 17p)
    212 4 2 2 0 dim (8p, 10q25.1qter) enh (8q, 11q)
    222 5 5 0 0 dim (1p, 9q, 10q, 14q, 18q)
    247 14 5 9 0 dim (5q, 6q, 10q?, 11p?, 18q) enh (6p, 8q21.3qter, 9p13.3q22.2, 11q12.1q13.5, 12p11.22q12.3, 14q23.2q31.3, 17q, 18p, 20)
    36 1 0 1 0 enh (5p?)
    77 3 2 1 0 dim (2q35qter, 3p) enh (5p)
    89 0 0 0 0 no changes
    129 8 3 4 1 dim (3p12p24, 5q31qter, 18q) enh (5p, 8, 12, 13q14.3q31.3) amp (11q21q23.1)
    138 14 9 5 0 dim (3q24pter, 4q23qter, 5q32qter, 6q, 7p11.2q21.3, 10q25.1qter, 11q14.1qter, 17p, 18q) enh (1p31.1q24.3, 3q26.1qter, 5p, 7p14.1pter, 17q)
    141 5 3 2 0 dim (8p, 16, 18q) enh (3q?, 8q)
    146 11 7 4 0 dim (3p, 5q23.1qter, 9q22.33qter, 10q23.2qter, 11p?, 15q22.1qter, 16p) enh (3q?, 5p, 6q, 12p)
    217 4 2 2 0 dim (4q28qter, 11q22.1qter) enh (17q, 18p)
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UC (n = 36)
    143 0 0 0 0 no changes
    J60 10 4 6 0 dim (2q32qter, 5q, 11p12pter,12p,Y) enh (3, 5p, 8q21.3q22.3, 
    J135 17 9 7 1 dim (2q14.2, 4p, 6q, 8p12pter, 11p, 13q13q31.3, 14q21qter, 16p, 18q) enh (1p31p1q32.2, 3q, 4q?, 5p, 7, 16q22.1qter, 18p, 20q) amp (8q23) 
    J178 16 7 9 0 dim(1p, 2q36qter, 5q, 6q, 8p, 10q, 18q) enh(1q, 5p, 6p22p24, 9p, 10p12pter, 13q31qter, 17q23.2qter, 18p, 20q)
    J223 9 3 6 0 dim (8p, 11q23qter, 18q21qter?) enh(3q24qter, 6p22pter, 8q, 9, 11p?, 18q, 14q)
    J224 4 3 1 0 dim (2q36qter, 10q, 11q22qter) enh(6p23pter)
    J228 0 0 0 0 no changes
    J578 0 0 0 0 no changes
    J311 0 0 0 0 no changes
    J66 3 1 2 0 dim (6q) enh(8q21.1qter, 11q14.3qter)
    J101 0 0 0 0 no changes
    J108 7 2 5 0 dim(4q32.1qter,12q21qter), enh(1q21q31,2q,3p25pter,5p,18p)
    J143 5 2 3 0 dim (6p22pter, 17p) enh (3q25q26, 8q, 9p23pter)
    J139 6 4 1 1 dim (4q31qter, 9, 15q22qter, 17p, Y) enh(7) amp(10q22q23)
    J381 8 4 4 0 dim (4p, 5q11.2q23, 8p, 18q) enh(5p, 8q, 10q25qter, 20)
    43 4 1 3 0 dim (10q22.2qter) enh (6q12q33, 8q, 17q)
    66 3 1 2 0 dim (8p) enh (5p, 10q23.1q24.1)
    45 5 3 2 0 dim (9?, 10q21.3qter, 18q) enh (8, 13q)
    179 15 12 3 0 dim (2q32.1qter, 3p12p24, 4p, 5q, 8p21pter, 10q, 11p, 11q23.1qter, 13q, 17p, 18q, 20p) enh (5p, 6q24pter, 10q)
    22 16 9 7 0 dim (3p?, 4p, 5q14.3q22.2, 6q14.1qter, 7p, 8p, 9q, 11p, 18q) enh (3q, 11q12.3q14.3, 12q12q21.33, 16, 17q, 18p, 20q)
    24 20 12 8 0 dim (2p22.3pter, 2q22.3q32.3, 4p, 4q32.3qter, 5q, 6q, 9p?, 9q, 10q24.2qter, 11p, 16p, 17p) enh (3q, 5p, 8q21.3q23.3, 11q12.1q14.1, 16q, 
17q11.1q23.2, 20)
    29 17 10 7 0 dim (2q14.1q24.3, 4p, 5q12.1q21.1, 5q33.2qter, 6q, 9q, 10q, 11p, 13q, 17p) enh (8q, 10p, 11q11q13.3, 12q11q21.33, 17q, 20)
    2 21 11 10 0 dim (1q31.1qter, 4p, 5q, 6q12q23.2, 8p, 9p, 9q, 10q24.2qter, 11p, 16q, 18q) enh 2q11.2q22.3, 3p24.1pter, 3q13.33q26.33, 4q31.1q34.2, 5p, 
6q23.2qter, 7p12.1q31.33, 10p, 16p, 18p)
    30 10 6 4 0 dim (3p13p24.1, 8p, 16p, 17p, 18q, 20p) enh (2q32.1q35, 8q21.13qter, 10p, 12p11.1p13.31)
    78 6 3 3 0 dim (8q23.1qter, 9, 14q) enh (1q, 2p16, 17q)
    77 7 4 3 0 dim (10q13.1qter, 15q21.1qter, 16p, 17p) enh (5p, 18p, 20p)
    71 4 1 3 0 dim (6q) enh (1q23.2q31.3, 5p, 18q)
    70 6 2 3 1 dim (11pX, 17p) enh (3q, 8q21.1qter, 10p) amp(12q14.1q23.1)
    47 11 5 6 0 dim (4q21.1qter, 6q, 7q21.3qter, 8p, 16q) enh (1q, 7p-q21.3, 8q22.2qter,9p, 10p, 17q)
    46 3 1 2 0 dim (3p?) enh (3q26.2qter, 17q24.3qter)
    44 7 4 3 0 dim (1p, 3p24.3, 6q, 8p, 11p) enh (8q, 17q, 18p)
    45 3 3 0 0 dim (10q, 11q22.3, 15q?)
    35 5 3 2 0 dim (4q31.3qter, 8p, 9q) enh (8q, 20p)
    32 9 7 2 0 dim (4q24qter, 5q32qter, 7p, 9p, 113q12.11q21.33, 17p, 18q) enh (10p, 18p)
    33 13 2 11 0 dim (2q34qter, 18q21.2qter) enh (1q42.3qter, 3q13.11q13.33, 7?, 8q11.22q23.3, 10q, 17, 18p, 20)
    34 5 5 0 0 dim (4?, 5q, 6q, 10q, 12q14.1q23.1)
n = number, p = short arm of chromosome, q = long arm of chromosome, dim = diminished, enh = enhanced, ? = inconclusive, ter = terminal. 
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CGH we performed traditional CGH in order to 
investigate as much cases as possible.
Amplification of DNA via degenerate oligonucle-
otide-primed-polymerase chain reaction (PCR) 
and Taq-polymerase primed-PCR, labeling with 
biotin-16-dUTP for tumor-DNA and digoxigenin-
11-dUTP for reference-DNA as well as hybridiza-
tion and detection were performed as described 
earlier [17]. Analysis included ten to fifteen 
metaphase-chromosomes per case.
Statistical analysis
Statistical analysis using Fisher’s exact test, 
1-way ANOVA-test and unbound t-Test was per-
formed with the GraphPad software (GraphPad 
Software, Inc., La Jolla, California, USA). 
Numbers are presented as frequencies and 
percentages. A P-value of less than 0.05 was 
considered significant. 
Results
Polysomy of tumor cells evaluated by FISH
For FISH-analysis n = 29 pure SqCC, n = 35 MIX 
and n = 23 UC could be successfully analyzed. 
Due to a low hybridization efficiency of tissue 
sections (<0.9) it was not possible to analyze 
deletions (p16-probe (gold)) with reasonable 
accuracy. Therefore, we only focused on poly-
somy of CEN3 (red), CEN7 (green) and CEN17 
(blue). Cells with ≥3 signals were assumed to 
be polysomic, and according to the formula: cut 
off = mean number of polysomic cells + (stand-
ard deviation × 3), the calculated cut-offs in 
normal cells for CEN3 (red) were 2.13, and for 
CEN7 (green) and CEN17 (blue) were 1.175 
each. All three tumor groups showed similar 
variations regarding the number of polysomic 
cells in all probes (Figure 1). Constantly, the 
mean number of polysomic cells in SqCC was 
lower, indicating less aneuploid tumor cells in 
SqCC compared to MIX and UC. Significant 
differences of polysomic and non-polysomic 
cases within the three groups were only found 
for the CEN3-probe (red) (P = 0.0498) and the 
CEN17-probe (aqua) (P = 0.0009). 
Differences of chromosome/locus copies 
among UC, MIX and SqCC 
Of all tumors 50 tumor cell nuclei were evalu-
ated for each probe; the mean results are 
shown in Figure 2. Means of the three tumor 
groups of the CEN3-probe (red) and the CEN17-
probe (blue) varied around 2, the CEN7-probe 
(green) was slightly below 2 and the means of 
the SPEC p16-probe (gold) was around 1. There 
was a slight tendency of lower copy numbers of 
chromosomes 3, 7 and 17 and higher numbers 
of the p16-locus in SqCC compared to UC and 
MIX, but there was no significant statistical 
difference among the three tumor groups (P = 
0.45). 
CGH of UC, MIX and SqCC 
CGH was successfully performed on n = 35 
SqCC, n = 40 MIX and n = 36 UC samples. 
Structural genomic variations were found in n = 
30 SqCC (85.7%), n = 35 MIX (87.5%) and n = 
32 UC samples (88.9%). Table 2 depicts all 
variations (Table 2). SqCC showed the lowest 
number of variations/tumor (mean = 5.37, 
standard error of the mean (SEM) 0.80, 95% 
confidence interval of the mean (CI) 3.75-6.99); 
MIX tumors had a mean of 6.75 changes/tumor 
(SEM 0.74, CI 5.25-8.25) and UC exhibited 
most changes with a mean of 7.64 changes/
tumor (SEM 0.98, CI 5.65-9.63; P = 0.1754, 
Figure 3).
Chromosomal variations of organ confined 
tumor stages (pT2) versus advanced tumor 
stages (pT3-4) 
In SqCCs mean number of changes increased 
with extravesical tumor stage (pT2 tumors: 
mean 3, SEM 1.48, CI-0.62-6.62; pT3-4 tumors: 
mean 5.964, SEM 0.90, CI 4.12-7.81). However, 
the case numbers for stages pT2 were low, and 
the difference was not statistically significant 
(P = 0.1386). In MIX and UC no increase of 
Figure 3. Mean of chromosomal aberrations for each 
tumor group in CGH. Each sample is represented by 
a symbol, mean of each tumor group is indicated by 
a horizontal line, standard error of the mean (SEM) is 
shown by a linked double horizontal line.
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changes with tumor stage could be found (MIX 
pT2: mean 8.9, SEM 2.72, CI 2.20-15.51; MIX 
pT3-4: mean 6.3, SEM 0.70, CI 4.88-7.72; P = 
0.1953; UC pT2: mean 9.2, SEM 1.60, CI 5.79-
12.56; UC pT3-4: 6.3, SEM 1.14, CI 3.88-8.65; 
P = 0.14).
Table 3. Gains and losses of short and long arms of chromosomes for each tumor group
Chr. arm
SqCC (n = 35) MIX (n = 40) UC (n = 36)
losses gains losses gains losses gains
n % n % n % n % n % n %
1p 1 2.9 2 5.7 3 7.5 4 10 2 5.5 1 2.8
1q 0 0 4 11.4 2 5 7 17.5 1 2.8 6 16.7
2p 1 2.9 1 2.9 3 7.5 1 2.5 1 2.8 1 2.8
2q 4 11.4 1 2.9 7 17.5 1 2.5 8 22.2 3 8.3
3p 18 51.4 2 5.7 15 37.5 1 2.5 5 13.9 3 8.3
3q 0 0 7 20 2 5 10 25 0 0 10 27.8
4p 4 11.4 0 0 3 7.5 0 0 8 22.2 0 0
4q 3 8.6 1 2.9 7 17.5 1 2.5 7 19.4 2 5.5
5p 1 2.9 4 11.4 0 0 16 40 0 0 11 30.6
5q 5 14.3 1 2.9 10 25 1 2.5 10 27.8 0 0
6p 0 0 3 8.6 4 10 3 7.5 1 2.8 3 8.3
6q 6 17.1 0 0 3 7.5 5 12.5 11 30.6 1 2.8
7p 0 0 3 8.6 1 2.5 5 12.5 2 5.5 5 13.9
7q 2 5.7 3 8.6 3 7.5 4 10 1 2.8 3 8.3
8p 9 25.7 1 2.9 6 15 2 5 12 33.3 1 2.8
8q 1 2.9 7 20 0 0 13 32.5 1 2.8 15 41.7
9p 2 5.7 4 11.4 4 10 2 5 6 16.7 4 11.1
9q 2 5.7 4 11.4 7 17.5 3 7.5 8 22.2 1 2.8
10p 1 2.9 2 5.7 0 0 5 12.5 0 0 8 22.2
10q 9 25.7 0 0 17 42.5 0 0 11 30.6 3 8.3
11p 1 2.9 1 2.9 9 22.5 1 2.5 9 25 1 2.8
11q 7 20 6 17.1 12 30 4 10 3 8.3 4 11.1
12p 0 0 4 11.4 0 0 7 17.5 1 2.8 1 2.8
12q 1 2.9 0 0 0 0 3 7.5 2 5.5 2 5.5
13p 0 0 0 0 0 0 0 0 0 0 0 0
13q 4 11.4 2 5.7 2 5 2 5 4 11.1 3 8.3
14p 1 2.9 1 2.9 0 0 0 0 0 0 0 0
14q 2 5.7 1 2.9 1 2.5 1 2.5 2 5.5 2 5.5
15p 0 0 0 0 0 0 0 0 0 0 0 0
15q 3 8.6 0 0 7 17.5 0 0 3 8.3 0 0
16p 2 5.7 1 2,9 7 17.5 2 5 4 11.1 2 5.5
16q 2 5.7 1 2.9 6 15 1 2.5 2 5.5 3 8.3
17p 2 5.7 2 5.7 7 17.5 3 7.5 9 25 1 2.8
17q 1 2.9 4 11.4 2 5 4 10 0 0 10 27.8
18p 1 2.9 7 20 0 0 4 10 0 0 9 25
18q 10 28.6 1 2.9 11 27.5 0 0 11 30.6 1 2.8
20p 3 8.6 3 8.6 3 7.5 4 10 2 5.5 6 16.7
20q 3 8.6 4 11.4 4 10 6 15 0 0 7 19.4
21p 1 2.9 1 2.9 0 0 0 0 0 0 0 0
21q 4 11.4 1 2.9 1 2.5 0 0 0 0 0 0
Chr. arm = chromosome arm, n = number, p = short arm of chromosome, q = long arm of chromosome, SqCC = pure squa-
mous cell carcinoma of the bladder, MIX = urothelial carcinoma with squamous differentiation, UC = urothelial carcinoma.
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Chromosomal variations and tumor grading
Correlations with tumor grade showed in all 
tumor groups the same trend of increasing 
genetic changes in less differentiated G3 
tumors compared to G2 tumors. In SqCCs G2 
tumours harboured a mean of 4.1 changes 
(SEM 1.44, CI 0.96-7.18), whereas G3 tumours 
showed a mean of 6.2 changes (SEM 0.90, CI 
4.37-8.11; P = 0.186). In mixed tumors there 
were 6.2 changes in G2 tumors (SEM 3.05, CI 
-1.67-14) and 6.9 changes in G3 tumors (SEM 
0.72, CI 5.39-8.32), and in pure UCs there was 
the same trend but there were only 2 cases of 
G2 tumours (G2: mean 15.5 changes, SEM 0.5, 
CI 9.12-21.85; G3: mean 7.17 changes, SEM 
0.98, CI 5.18-9.17). Due to low numbers no sta-
tistical analysis was performed.  
Most frequent chromosomal changes
Table 3 shows an overview of the gains and 
losses on short (p) and long (q) arms of the 
chromosomes compared in each tumor group 
(Table 3). Chromosomes 19, 22, X and Y were 
excluded due to high variability.
Most frequent changes in SqCC were losses of 
3p (51.4%)*, 8p (25.7%), 10q (25.7%), 18q 
(28.6%), and gains of 3q (20%), 8q (20%), 18p 
(20%). In MIX tumors losses were found on 3p 
(37.5%), 5q (25%), 10q (42.5%), 11p (22.5%)*, 
11q (30%) and 18q (27.5%), and gains on 3q 
(25%), 5p (40%) and 8q (32.5%). UCs presented 
with the most frequent losses on 5q (27.8%), 
6q (30.6%)*, 8p (33.3%), 9q (22.2%), 10q 
(30.%), 11p (25%)*, 17p (25%) and 18q (30.6%), 
as well as gains on 3q (27.8%), 5p (30.6%), 8q 
(41.7%), 10p (22.2%), 17q (27.8%) und 18p 
(25%). In statistical analysis significant differ-
ences between groups were found for losses 
on 3p (P = 0.0041), 6q (P = 0.0202) and 11p (P 
= 0.0237), as well as for gains on 5p (P = 
0.0202). 
Discussion
This is the first larger study comparing immuno-
histochemically proven non-schistosoma asso-
ciated pure SqCC, mixed urothelial carcinoma 
with partial squamous differentiation and pure 
UC. In previous studies either not exactly char-
acterized/specified tumors or only small num-
bers of cases have been analyzed. Our data 
support the concept that SqCC of the bladder is 
less aneuploid and therefore genetically more 
stable than UC. This is in line with the largest 
non-specified FISH-study of cell suspensions of 
n = 94 SCCs and n = 96 UCs from Pycha et al., 
who also found less polysomic tumour cells in 
SqCCs than in UCs (CEN17 30.8% versus 85.4% 
UC, CEN 7 81.9% vs. 97.9%) [18]. For chromo-
some 7 our study could not show statistically 
significant differences. However, this might be 
due to the technical difference of cell suspen-
sions and artifact-rich tissue sections (partial 
nuclei or overlay of nuclei) [19]. Further, 
Urovysion® FISH was developed for the detec-
tion of aneuploidy in UC, and Reid Nicholson et 
al. found only two of 15 SqCCs on tissue sec-
tions FISH-positive (Abbott criteria), strongly 
questioning its diagnostic value in non-urotheli-
al tumors. However, analysis of their published 
data also showed polysomies of chromosome 3 
and 17 in one case, as well as polysomy of chro-
mosomes 3, 7 and 17 in the other case [20]. In 
contrast, we found higher numbers of positive 
SqCCs (22/29, 76%) and polysomic tumor cells: 
76% of cases showed polysomy of chromo-
some 3 and 68% polysomy of chromosome 17. 
Kipp et al. analyzed tissue sections of n = 7 
SqCC by Urovysion® FISH and detected homozy-
gous deletions of 9p21 in SqCC significantly 
more frequent than in other tumor types [21]. 
They also reported polysomies of the other 
chromosomes in 31% of 9p21-deleted cells. 
We substantiated our study with further analy-
sis of our cohort by CGH. Similar to UC [22] we 
expected an increase of genetic alterations by 
tumor stage and grade in squamous tumors as 
a consequence of accumulation of genetic hits. 
However, in our invasive cancers we found no 
significant correlations of genetic alterations 
within any tumor group regarding increasing 
tumor stage (T2 vs. T3-4) or grade (G2 vs. G3). 
Overall we detected less genetic alterations in 
SqCC (mean 5.37) than in any other tumor type 
(MIX mean 6.75, UC mean 7.64), but the results 
showed no statistical significance. The findings 
are similar to the differences in tumor cell poly-
somy found with FISH. 
An important question is, if there is a difference 
in the genetic profile of schistosoma- and non-
schistosoma-associated-SqCC. Comparing our 
non-schistosoma associated samples to the 
reported schistosoma-associated data [3], we 
found losses of 3p, 8p, 8q and 18q in both set-
tings. El Rifai et al. also compared schistoso-
ma- and non-schistosoma-associated samples 
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and detected in non-schistosoma-associated 
samples most frequently losses of 13q, 3p, 9p 
and gains of 1q, 8q and 20q [3, 14]. The results 
for the losses of 3p and gains of 8q are in line 
with ours, however, we found alterations of 3p 
much more frequently (51% vs. El-Rifai et al. 
18%). Alterations of chromosomes 9p and 13q 
as well as 1q and 20q were not among the 
most frequent alterations in our study.
Another point to address is, whether there is a 
specific difference in genetic aberrations in 
SqCC and MIX or UC. The earlier study of Rifai 
et al. dealing with not-exactly characterized 
samples reported gains and high-level amplifi-
cations of 5p and losses of 3p as specific for 
SqCC, with gains of 5p only in schistosoma-
associated SqCC [14]. Our precisely defined 
cohort showed three characteristics: a) the loss 
of 3p was more frequent in SqCC than in MIX or 
UC, b) the loss of 11p was less frequent in 
SqCC than in others, and c) there were less 
gains of 5p in SqCC compared to MIX and UC (P 
= 0.0795). However, we found gains of 5p in 
30% of UC. Loss of chromosome arm 11p was 
rare in all groups in the study of El-Rifai et al. 
[14]. Fadl-Elmula et al. analyzed two cases of 
urothelial carcinoma with secondary squamous 
differentiation. They showed in both cases 
UC-typical changes and an isochromosome 5p 
in one case and the loss of 11p in the other 
case, which allowed no discrimination between 
MIX and UC [13]. The loss of 3p was also report-
ed in squamous cell tumors of the head and 
neck [23] and esophagus [24, 25], with a 
reported loss of 57% (21/37) in SqCC of the 
esophagus [25]. In a meta-analysis of CGH 
data of 5918 cancers Baudis et al. described 
frequent losses of 3p and gains of 3q, 8q as 
well as variable gains of 1q and 5p in cancer 
subsites with predominantly squamous cell 
tumours (i.e., head and neck, non-small cell 
lung cancer, cervix carcinoma, vulva carcino-
ma, esophagus carcinoma) [23]. Interestingly, 
in our analysis we also found frequent loss of 
3p and gains of 3q, 8q and 5p, but more often 
in UC than in SqCC, which does not indicate a 
specific role in squamous cell cancers but a 
general involvement in the malignant transfor-
mation of the urothelium. 
Comparing the exact regions of losses in 3p, we 
found more often a complete loss of 3p or from 
3p14 until the p-terminal end in SqCC, whereas 
the losses in MIX and UC are more focal. There 
are various genes located in region 3p, e.g., 
FHIT (fragile histidine triad-3p14.2), CTNNB1 
catenin (cadherin associated protein-3p21), 
VHL (von Hippel-Lindau tumor suppressor, E3 
ubiquitin protein ligase-3p25.3) [25], or MLH1 
(mutL homolog 1, colon cancer  nonpolyposis 
type 2-3p21.3) [23]. So far, only FHIT was 
reported to be involved in the tumorigenesis of 
bladder tumors [26]. It encodes the FHIT-
protein, a diadenosintriphosphate-hydrolase of 
the “histidine triad (HIT)”-super family of nucle-
otid-binding proteins [26, 27], which acts as a 
tumour suppressor. The tumour suppressive 
mechanism is not fully understood, yet [26, 28, 
29], but it seems to induce apoptosis [29], and 
interacts with several pathways regulating oxi-
dative stress and cell cycle control [28, 29]. 
Furthermore, region 3p14.2 includes a very 
active “common fragile site (CFS)” FRA3B, sus-
ceptible for strand breaks or rearrangements 
(genetic instability), and triggering tumorigene-
sis [28, 29]. Therefore, loss of 3p14.2 as part 
of FRA3 is reported quite often in tumours of 
the lung, esophagus, cervix, breast and head 
and neck [26, 28]. In bladder tumors Han et al. 
reported a negative correlation of FHIT expres-
sion with tumour grade, but not with tumour 
stage or recurrence [26]. Zhang et al. suggest-
ed FHIT expression as a prognostic marker, as 
patients with positive FHIT-expression showed 
significantly longer survival times in their study 
[30]. FHIT-expression has not yet been investi-
gated in pure, non-schistosoma associated 
SqCCs of the bladder, but Gutierrez et al. found 
a methylation of FHIT (40% of cases) and other 
loci in schistosoma-associated SqCCs [31].
To conclude, SqCCs show less polysomy and 
genetic alterations than MIX and UC. However, 
the structural genetic profile for SqCC, MIX and 
UC is similar, with no absolutely specific altera-
tions for each group. Loss of 3p was more fre-
quent in SqCC, but so far we do not know the 
driver-event for squamous carcinogenesis. Our 
results build bridges to the recently proposed 
subtypes of muscle invasive bladder cancer, as 
the described “basal/squamous-like” subtype 
perfectly overlaps with our MIX tumors, espe-
cially the “transdifferentiated” subtype of Gaisa 
et al. [15]. Our cytogenetic data strengthen the 
concept of different squamous phenotypes in 
bladder cancer: mixed tumors show similar 
alterations than UC, thus seem to fit into the 
“squamous-like” subtype and should be con-
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sidered a further more aggressive development 
of urothelial carcinoma, while mere SqCC 
appear to be a separate tumor group. Gathering 
detailed knowledge on exact subtypes of blad-
der cancer is extremely important for the devel-
opment of biology-based individualized thera-
pies and further molecular studies on squa-
mous differentiated bladder tumours are 
needed.
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